Researchers from Oxford's Ludwig Institute for Cancer Research and de Duve Institute have found out that drugs used to treat hypertension could substantially improve the clinical efficacy of cancer immunotherapy. They discovered a new treatment approach that helps T lymphocytes to destroy cancerous cells.
A team led by Alex Clarke at the Kennedy Institute has identified how high mitochondrial activity regulates antibody responses crucial for immunity but is also necessary for the development of lymphoma.
New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient\u2019s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.
The partnership will aim to apply new immunotherapy techniques to cancer patients. It will also aim to enhance scientific outcomes in both institutions, sharing strategic initiatives and supporting clinical trials.
The NIHR Oxford Biomedical Research Centre (BRC), a partnership between the University of Oxford and Oxford University Hospitals (OUH) NHS Foundation Trust, will receive \u00a386.6m over the next five years to fund 15 research themes.
As part of World Cancer Day 2022 we are diving into 10 of Oxford\u2019s most impactful historical and modern contributions to the field of cancer science and treatment. Read more about what Oxford researchers have done to shape this ever-important area of medical science.
The first patient has been dosed in the MAGE trial, which is testing a novel immunotherapeutic known as VTP-600, in patients with the most common type of lung cancer.
Professor Yang Shi\u2019s laboratory uncovers an important role for the chromatin regulator LSD1 in T cell exhaustion and demonstrates that LSD1 inhibition in mice increases the durability of responses to immune checkpoint blockade therapy.
A study from the Fairfax lab provides new insight into the factors that determine patient response to Immune Checkpoint Blockers, a common immunotherapy treatment for melanoma.
A new publication from Benoit Van den Eynde's group has shown that a viral vector cancer vaccine generates effective anti-tumour immune responses and, in combination with immunotherapy, decreases tumour size and increases survival rates in mouse models.
Prostate Cancer UK have invested \u00a31.7 million into five immunotherapy projects, including two from Profs Kate Vallis, Richard Bryant and Eileen Parkes at the University of Oxford. Read about their funded work.
The first patient has been dosed using new drug PORT-2 in Oxford, which hopes to improve treatment options for melanoma and Non-Small Cell Lung Cancer (NSCLC) and resensitise patients with checkpoint therapy-resistant tumours
The Seymour lab at the Department of Oncology, University of Oxford, has published a new paper investigating the use of oncolytic herpes virus-1 as a vector to augment immunotherapy in cancer
Co-funded by Cancer Research UK and Children with Cancer UK, Andi is one of 5 to receive \u00a31 million each to investigate children\u2019s and young people\u2019s cancers.
Christina Ye has been awarded CRUK pre-doctoral fellowship, she tells us about her upcoming project into T cell trafficking between the blood and skin when patients undergo checkpoint immunotherapy
Susan Cakebread, gives her account of being on the Tebentafusp experimental immunotherapy drug trial in 2014. A Phase 1 trial for melanoma that began here in Oxford, and is now entering Phase 3 trials after giving Susan back her life.
Understanding how an individual survives cancer, and why they respond well to therapy, can be vital in identifying new therapeutic targets. A new project seeks to see why some advanced pancreatic cancer patients overcome the odds and respond positively to treatment.
![\"Immunotherapy](\"https://www.cancer.ox.ac.uk/news/hypertension-drugs-could-improve-cancer-immunotherapy-efficacy/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n